Biogen, UCB release phase 3 data on lupus candidate dapirolizumab

seekingalpha11-20

Michail_Petrov-96A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484975191?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/654956612/image_654956612.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-11-20 01:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484975191","market":"nz","top_or_hot":-1,"title":"Biogen, UCB release phase 3 data on lupus candidate dapirolizumab","media":"seekingalpha","content":"<div>\n<p>Michail_Petrov-96A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant ...</p>\n\n<a href=\"https://seekingalpha.com/news/4307964-biogen-ucb-release-phase-3-data-lupus-candidate-dapirolizumab\">Source Link</a>\n\n</div>\n","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen, UCB release phase 3 data on lupus candidate dapirolizumab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen, UCB release phase 3 data on lupus candidate dapirolizumab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 01:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4307964-biogen-ucb-release-phase-3-data-lupus-candidate-dapirolizumab><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Michail_Petrov-96A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant ...</p>\n\n<a href=\"https://seekingalpha.com/news/4307964-biogen-ucb-release-phase-3-data-lupus-candidate-dapirolizumab\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRI","symbol_name":"Stoneridge Inc","start_time":0,"source_url":"https://seekingalpha.com/news/4307964-biogen-ucb-release-phase-3-data-lupus-candidate-dapirolizumab","article_id":"2484975191","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/654956612/image_654956612.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484975191","pubTimestamp":1732038475,"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"Michail_Petrov-96A phase 3 trial of Biogen  and UCB's  dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in disease activity. In the study, DZP was given intravenously every four weeks for 48 weeks. Results showed that those on DZP plus standard of care had a statistically significant response rate of 49.5% compared to 34.6% for those on standard of care alone based on the British Isles Lupus Assessment Group -based Composite Lupus Assessment . While a key secondary endpoint, BICLA response at week 24, showed that participants on DZP plus SOC had a 7.9% higher response rate than those on SOC alone, the difference was not statistically significant. Analyses of other secondary endpoints showed better improvement in the DZP group compared to the SOC group in SLE Responder Index -4 response, corticosteroid tapering, SLE Disease Activity Index-2K , achievement of Lupus Low Disease Activity State , and prevention of severe BI","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SRI":"Stoneridge Inc","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","BK4124":"机动车零配件与设备","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","BIIB":"渤健公司","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4211":"区域性银行","BK4007":"制药","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","UCB":"美国社区银行","SRI.AU":"SIPA RESOURCES LTD","UCBJF":"UCB S.A.","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","UCBJY":"UCB S.A.","BK7095":"多种金属与采矿"},"translate_title":"Biogen和UCB发布狼疮候选药物dapirolizumab的3期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UCBJY":1,"UCBJF":1,"UCB":1,"SRI.AU":1,"SRI":1,"BIIB":1},"content_text":"Michail_Petrov-96A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in disease activity. In the study, DZP was given intravenously every four weeks for 48 weeks. Results showed that those on DZP plus standard of care had a statistically significant response rate of 49.5% compared to 34.6% for those on standard of care alone based on the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA). While a key secondary endpoint, BICLA response at week 24, showed that participants on DZP plus SOC had a 7.9% higher response rate than those on SOC alone, the difference was not statistically significant. Analyses of other secondary endpoints showed better improvement in the DZP group compared to the SOC group in SLE Responder Index (SRI)-4 response, corticosteroid tapering, SLE Disease Activity Index-2K (SLEDAI-2K), achievement of Lupus Low Disease Activity State (LLDAS), and prevention of severe BILAG flares. Biogen said the safety profile of DZP was generally favorable. The biotech noted that it and UCB will begin a second phase 3 trial by the end of the year.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484975191"}